131 related articles for article (PubMed ID: 34114691)
21. Randomized, trough blood cyclosporine concentration-controlled trial to compare the pharmacodynamics of Sandimmune and Neoral in de novo lung transplant recipients.
Trull A; Steel L; Sharples L; Stewart S; Parameshwar J; McNeil K; Wallwork J
Ther Drug Monit; 1999 Feb; 21(1):17-26. PubMed ID: 10051050
[TBL] [Abstract][Full Text] [Related]
22. Graft function based on two hours peak level monitoring of cyclosporine A during the first six months of renal transplantation.
Hami M; Naghibi M; Mojahedi MJ; Sharifipour F; Shakeri MT
Saudi J Kidney Dis Transpl; 2012 Nov; 23(6):1169-74. PubMed ID: 23168844
[TBL] [Abstract][Full Text] [Related]
23. Comparison of pharmacokinetics of cyclosporine A in cadaveric and living-related renal transplant recipients and in an experimental rat model of renal failure.
Sugioka N; Fujimoto K; Tanaka Y; Fukushima K; Ito Y; Kokuhu T; Okamoto M; Yoshimura N; Takada K
Drug Metab Lett; 2009 Aug; 3(3):152-61. PubMed ID: 19702545
[TBL] [Abstract][Full Text] [Related]
24. Development and validation of limited sampling strategies for estimation of cyclosporine area under the concentration-time curve in hematopoietic stem cell transplant patients.
Hadjibabaie M; Vazirian I; Iravani M; Moosavi SA; Alimoghaddam K; Ghavamzadeh A; Rezaee S
Ther Drug Monit; 2011 Dec; 33(6):673-80. PubMed ID: 22011723
[TBL] [Abstract][Full Text] [Related]
25. Cyclosporine A (CsA) 2-h concentrations vary between patients without correlation to graft-versus-host disease after allogeneic haematopoietic stem cell transplantation.
Barkholt L; Remberger M; Bodegård H; Ringdén O; Böttiger Y
Bone Marrow Transplant; 2007 Oct; 40(7):683-9. PubMed ID: 17660840
[TBL] [Abstract][Full Text] [Related]
26. A retrospective analysis of mycophenolic acid and cyclosporin concentrations with acute rejection in renal transplant recipients.
Pillans PI; Rigby RJ; Kubler P; Willis C; Salm P; Tett SE; Taylor PJ
Clin Biochem; 2001 Feb; 34(1):77-81. PubMed ID: 11239520
[TBL] [Abstract][Full Text] [Related]
27. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
[TBL] [Abstract][Full Text] [Related]
28. The area under the concentration-time curve versus trough and peak blood level monitoring in renal transplant recipients on cyclosporine.
Halim MA; Nampoory MR; Johny KV; Donia F; Hamid MH; Said T; Nair MP; Mansour M; Al-Muzairai I; Samhan M; Al-Mousawi M
Transplant Proc; 2005 Sep; 37(7):3019-21. PubMed ID: 16213291
[TBL] [Abstract][Full Text] [Related]
29. A Limited Sampling Strategy for Therapeutic Drug Monitoring of Mycophenolate Mofetil for Prophylaxis of Acute Graft-Versus-Host Disease in Allogeneic Stem Cell Transplantation.
Gota V; Purohit V; Gurjar M; Nayak L; Punatar S; Gokarn A; Bonda A; Bagal B; Vora CS; Patil A; Nookala M; Khattry N
Cell Transplant; 2020; 29():963689720912925. PubMed ID: 32495641
[TBL] [Abstract][Full Text] [Related]
30. A limited sampling model for estimation of total and unbound mycophenolic acid (MPA) area under the curve (AUC) in hematopoietic cell transplantation (HCT).
Ng J; Rogosheske J; Barker J; Weisdorf D; Jacobson PA
Ther Drug Monit; 2006 Jun; 28(3):394-401. PubMed ID: 16778725
[TBL] [Abstract][Full Text] [Related]
31. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
32. Relationship between cyclosporine area-under-the curve and acute graft versus host disease in pediatric patients undergoing hematopoietic stem cell transplant: A prospective, multicenter study.
Schechter T; Lewis VA; Schultz KR; Mitchell D; Chen S; Seto W; Teuffel O; Gibson P; Doyle JJ; Gassas A; Sung L; Lee Dupuis L
Pediatr Hematol Oncol; 2018 May; 35(4):288-296. PubMed ID: 30592246
[TBL] [Abstract][Full Text] [Related]
33. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.
Musuamba FT; Rousseau A; Bosmans JL; Senessael JJ; Cumps J; Marquet P; Wallemacq P; Verbeeck RK
Clin Pharmacokinet; 2009; 48(11):745-58. PubMed ID: 19817503
[TBL] [Abstract][Full Text] [Related]
34. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.
van Gelder T; Hilbrands LB; Vanrenterghem Y; Weimar W; de Fijter JW; Squifflet JP; Hené RJ; Verpooten GA; Navarro MT; Hale MD; Nicholls AJ
Transplantation; 1999 Jul; 68(2):261-6. PubMed ID: 10440399
[TBL] [Abstract][Full Text] [Related]
35. Cyclosporine A trough concentrations are associated with acute GvHD after non-myeloablative allogeneic hematopoietic cell transplantation.
de Kort EA; de Lil HS; Bremmers MEJ; van Groningen LFJ; Blijlevens NMA; Huls G; Brüggemann RJM; van Dorp S; van der Velden WJFM
PLoS One; 2019; 14(3):e0213913. PubMed ID: 30897127
[TBL] [Abstract][Full Text] [Related]
36. ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients.
García M; Macías RM; Cubero JJ; Benítez J; Caravaca F; Gervasini G
Eur J Clin Pharmacol; 2013 Mar; 69(3):385-93. PubMed ID: 22886152
[TBL] [Abstract][Full Text] [Related]
37. Monitoring C2 level predicts exposure in maintenance lung transplant patients receiving the microemulsion formulation of cyclosporine (Neoral).
Jaksch P; Kocher A; Neuhauser P; Sarahrudi K; Seweryn J; Wisser W; Klepetko W
J Heart Lung Transplant; 2005 Aug; 24(8):1076-80. PubMed ID: 16102443
[TBL] [Abstract][Full Text] [Related]
38. Cyclosporine levels > 195 μg/L on day 10 post-transplant was associated with significantly reduced acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Bianchi M; Heim D; Lengerke C; Halter J; Gerull S; Kleber M; Tsakiris DA; Passweg J; Tzankov A; Medinger M
Ann Hematol; 2019 Apr; 98(4):971-977. PubMed ID: 30542943
[TBL] [Abstract][Full Text] [Related]
39. Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue.
Giralt S; Weber D; Colome M; Dimopoulos M; Mehra R; Van Besien K; Gajewski J; Andersson B; Khouri I; Przepiorka D; von Wolff B; Delasalle K; Korbling M; Seong D; Alexanian R; Champlin R
J Clin Oncol; 1997 Feb; 15(2):667-73. PubMed ID: 9053492
[TBL] [Abstract][Full Text] [Related]
40. Value of therapeutic drug monitoring of MMF therapy in pediatric transplantation.
Filler G
Pediatr Transplant; 2006 Sep; 10(6):707-11. PubMed ID: 16911495
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
